BR112022024294A2 - Bioconjugado shigella-tetravalente (shigella4v)". - Google Patents
Bioconjugado shigella-tetravalente (shigella4v)".Info
- Publication number
- BR112022024294A2 BR112022024294A2 BR112022024294A BR112022024294A BR112022024294A2 BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2 BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A BR112022024294 A BR 112022024294A BR 112022024294 A2 BR112022024294 A2 BR 112022024294A2
- Authority
- BR
- Brazil
- Prior art keywords
- shigella
- shigella4v
- bioconjugate
- tetravalent
- composition
- Prior art date
Links
- 241000607768 Shigella Species 0.000 abstract 3
- 241000607762 Shigella flexneri Species 0.000 abstract 1
- 241000607760 Shigella sonnei Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940115939 shigella sonnei Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063040844P | 2020-06-18 | 2020-06-18 | |
| US202063043883P | 2020-06-25 | 2020-06-25 | |
| EP20182138 | 2020-06-25 | ||
| EP20182139 | 2020-06-25 | ||
| PCT/IB2021/055361 WO2021255684A1 (en) | 2020-06-18 | 2021-06-17 | Shigella-tetravalent (shigella4v) bioconjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022024294A2 true BR112022024294A2 (pt) | 2023-02-28 |
Family
ID=76502778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022024294A BR112022024294A2 (pt) | 2020-06-18 | 2021-06-17 | Bioconjugado shigella-tetravalente (shigella4v)". |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230346902A1 (https=) |
| EP (1) | EP4168040A1 (https=) |
| JP (1) | JP2023530154A (https=) |
| CN (1) | CN115697396A (https=) |
| BR (1) | BR112022024294A2 (https=) |
| CA (1) | CA3185719A1 (https=) |
| MX (1) | MX2022016587A (https=) |
| WO (1) | WO2021255684A1 (https=) |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| KR20090110951A (ko) | 2002-03-07 | 2009-10-23 | 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 | 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계 |
| CA2607595C (en) | 2005-05-11 | 2018-11-27 | Eth Zuerich | Recombinant n-glycosylated proteins from procaryotic cells |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| CA2671709C (en) | 2006-12-13 | 2016-08-16 | The Governors Of The University Of Alberta | Methods and systems for o-glycosylating proteins |
| HRP20181259T1 (hr) | 2008-02-20 | 2018-10-05 | Glaxosmithkline Biologicals S.A. | Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica |
| EP2501406B8 (en) | 2009-11-19 | 2018-01-24 | GlaxoSmithKline Biologicals S.A. | Biosynthetic system that produces immunogenic polysaccharides in prokaryotic cells |
| CN110423716A (zh) * | 2012-10-12 | 2019-11-08 | 葛兰素史密丝克莱恩生物有限公司 | 宿主细胞修饰方法 |
| CA2889767C (en) * | 2012-11-07 | 2021-09-21 | Glycovaxyn Ag | Production of recombinant vaccine in e. coli by enzymatic conjugation |
| CN106535927B (zh) | 2014-02-24 | 2019-09-20 | 葛兰素史密丝克莱恩生物有限公司 | 新颖多糖及其用途 |
| ES2672045T3 (es) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas |
| CN105695497B (zh) | 2014-11-27 | 2019-09-24 | 中国人民解放军军事医学科学院生物工程研究所 | 一种细菌多糖修饰的重组融合蛋白的制备方法及其应用 |
| EP3310381B1 (en) * | 2015-06-16 | 2023-06-07 | GlaxoSmithKline Biologicals SA | Immunogenic compositions |
| GB201518668D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Immunogenic Comosition |
-
2021
- 2021-06-17 MX MX2022016587A patent/MX2022016587A/es unknown
- 2021-06-17 WO PCT/IB2021/055361 patent/WO2021255684A1/en not_active Ceased
- 2021-06-17 CN CN202180043251.6A patent/CN115697396A/zh active Pending
- 2021-06-17 JP JP2022577503A patent/JP2023530154A/ja active Pending
- 2021-06-17 CA CA3185719A patent/CA3185719A1/en active Pending
- 2021-06-17 US US18/001,551 patent/US20230346902A1/en active Pending
- 2021-06-17 BR BR112022024294A patent/BR112022024294A2/pt unknown
- 2021-06-17 EP EP21733220.4A patent/EP4168040A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021255684A1 (en) | 2021-12-23 |
| EP4168040A1 (en) | 2023-04-26 |
| CN115697396A (zh) | 2023-02-03 |
| CA3185719A1 (en) | 2021-12-23 |
| MX2022016587A (es) | 2023-02-01 |
| US20230346902A1 (en) | 2023-11-02 |
| JP2023530154A (ja) | 2023-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hoffmann et al. | The Yersinia pseudotuberculosis cytotoxic necrotizing factor (CNFY) selectively activates RhoA | |
| EA202092003A1 (ru) | Соединения для лечения болезни гентингтона | |
| BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
| CY1119376T1 (el) | Αντισωματα ειδικα για τη μορφη πρωτοϊνιδιου της βητα-αμυλοειδους πρωτεϊνης | |
| BR112023023671A2 (pt) | Composições imunogênicas compreendendo antígenos de sacarídeo capsular conjugados e usos dos mesmos | |
| BR0211926A (pt) | agentes para realçar a resposta imune | |
| PE20110023A1 (es) | Composiciones inmunogenicas de antigenos de staphylococcus aureus | |
| CY1118258T1 (el) | Εντεροδιαλυτη συνθεση για την παρασκευη περιβληματος μαλακης καψουλας | |
| DE602006017225D1 (de) | Erbsenproteinzusammensetzung | |
| BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
| HK1212249A1 (en) | Bioconjugates comprising modified antigens and uses thereof | |
| CY1114716T1 (el) | Ανασυσταθεντα επιφανειοδραστικα τα οποια διαθετουν βελτιωμενες ιδιοτητες | |
| BR112018010394A8 (pt) | anticorpo, conjugado anticorpo-fármaco, composição farmacêutica, e, combinação do anticorpo. | |
| Wang et al. | Protein changes in Trichinella spiralis muscle larvae in vitro induced by bovine bile | |
| BR112014015390A2 (pt) | vírus da estomatite vesicular para vacinas iniciais e de reforço | |
| Wang et al. | Protein change of intestinal epithelial cells induced in vitro by Trichinella spiralis infective larvae | |
| BR0113915A (pt) | Uso de adenil ciclase da espécie bordetella, composição imunogênica ou farmacêutica, uso da mesma, e , vetor proteináceo | |
| BR112022024294A2 (pt) | Bioconjugado shigella-tetravalente (shigella4v)". | |
| Bao et al. | Ovomucin hydrolysates reduce bacterial adhesion and inflammation in enterotoxigenic Escherichia coli (ETEC) K88-challenged intestinal epithelial cells | |
| Wang et al. | Commensals serve as natural barriers to mammalian cells during Acanthamoeba castellanii invasion | |
| BR0315620A (pt) | Derivados de n-benzodioxolil, n-benzodioxanil e n-benzodioxepinil arilcarboxamida, e composições farmacêuticas compreendendo os mesmos | |
| CO2022003789A2 (es) | Composiciones inmunogénicas contra enfermedades entéricas y métodos para su preparación | |
| Fukasawa et al. | Immune response to native NadA from Neisseria meningitidis and its expression in clinical isolates in Brazil | |
| EA201892254A1 (ru) | Экстракт табачного листа и его применение для лечения табачной зависимости | |
| BR112017010894A2 (pt) | processo cosmético, polímero de polissacarídeo e composição |